Compare OPEN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPEN | FTRE |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2020 | 2023 |
| Metric | OPEN | FTRE |
|---|---|---|
| Price | $2.00 | $23.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 13 |
| Target Price | $4.27 | ★ $21.46 |
| AVG Volume (30 Days) | ★ 28.5M | 1.5M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,371,000,000.00 | $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $90.27 | $3.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $1.93 | $8.55 |
| 52 Week High | $9.44 | $24.36 |
| Indicator | OPEN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 31.90 | 70.32 |
| Support Level | N/A | $15.94 |
| Resistance Level | $2.81 | N/A |
| Average True Range (ATR) | 0.16 | 1.28 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 15.45 | 75.37 |
Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital-light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.